Sat, Jul 26, 2014, 3:18 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Bovie Medical Corporation Message Board

  • wise2allofu wise2allofu Oct 23, 2012 10:13 PM Flag

    10K March 29, 2012 Reminder Reminder

    It has been 208 days, 57% of a year and/or more than 2 financial quarters.

    29-Mar-12
    In other developments, the Company announced today that it has signed several interim and related product development agreements with a major multi-national medical device company in anticipation of a final developmental and manufacturing agreement expected to be completed in the second quarter this year.

    Jeff Rencher, Vice President of Sales and Marketing of Surgical Products heading up the marketing of J-Plasma™ commented that, “After recently presenting J-Plasma™ at the World Robotic Gynecological Congress and the International Society for Gynecologic Endoscopy, we are even more confident in the technology’s potential. The interest demonstrated by surgeons at these trade shows indicates a need for J-Plasma™. Our plan is to deliver the product in the coming weeks to select surgeons that range from world renowned surgical instructors to surgeons with previous experience in inert gas plasmas, then shortly after offering it to the U.S. surgical marketplace. Although Gynecology is our initial focus, we expect to target additional medical procedures in the General, Plastics and Urology markets as well.”

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • It has been 208 days, 57% of a year and/or more than 2 financial quarters.

      29-Mar-12
      In other developments, the Company announced today that it has signed several interim and related product development agreements with a major multi-national medical device company in anticipation of a final developmental and manufacturing agreement expected to be completed in the second quarter this year.

      Jeff Rencher, Vice President of Sales and Marketing of Surgical Products heading up the marketing of J-Plasma™ commented that, “After recently presenting J-Plasma™ at the World Robotic Gynecological Congress and the International Society for Gynecologic Endoscopy, we are even more confident in the technology’s potential. The interest demonstrated by surgeons at these trade shows indicates a need for J-Plasma™. Our plan is to deliver the product in the coming weeks to select surgeons that range from world renowned surgical instructors to surgeons with previous experience in inert gas plasmas, then shortly after offering it to the U.S. surgical marketplace. Although Gynecology is our initial focus, we expect to target additional medical procedures in the General, Plastics and Urology markets as well.”

 
BVX
3.82+0.02(+0.53%)Jul 25 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.